Unknown

Dataset Information

0

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.


ABSTRACT: Effective treatment options in advanced/progressive/metastatic medullary thyroid carcinoma (MTC) are currently limited. As in other neuroendocrine neoplasms (NENs), peptide receptor radionuclide therapy (PRRT) has been used as a therapeutic option in MTC. To date, however, there are no published reviews dealing with PRRT approaches. We performed an in-depth narrative review on the studies published in this field and collected information on registered clinical trials related to this topic. We identified 19 published studies, collectively involving more than 200 patients with MTC, and four registered clinical trials. Most cases of MTC were treated with PRRT with somatostatin analogues (SSAs) radiolabelled with 90 yttrium (90Y) and 177 lutetium (177Lu). These radiopharmaceuticals show efficacy in the treatment of patients with MTC, with a favourable radiological response (stable disease, partial response or complete response) in more than 60% of cases, coupled with low toxicity. As MTC specifically also expresses cholecystokinin receptors (CCK2Rs), PRRT with this target has also been tried, and some randomised trials are ongoing. Overall, PRRT seems to have an effective role and might be considered in the therapeutic strategy of advanced/progressive/metastatic MTC.

SUBMITTER: Grossrubatscher E 

PROVIDER: S-EPMC7693147 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy.

Grossrubatscher Erika E   Fanciulli Giuseppe G   Pes Luca L   Sesti Franz F   Dolci Carlotta C   de Cicco Federica F   Colao Annamaria A   Faggiano Antongiulio A   Nike Group  

Journal of clinical medicine 20201029 11


Effective treatment options in advanced/progressive/metastatic medullary thyroid carcinoma (MTC) are currently limited. As in other neuroendocrine neoplasms (NENs), peptide receptor radionuclide therapy (PRRT) has been used as a therapeutic option in MTC. To date, however, there are no published reviews dealing with PRRT approaches. We performed an in-depth narrative review on the studies published in this field and collected information on registered clinical trials related to this topic. We id  ...[more]

Similar Datasets

| S-EPMC9197113 | biostudies-literature
| S-EPMC5749122 | biostudies-literature
| S-EPMC8139052 | biostudies-literature
| S-EPMC3991004 | biostudies-literature
| S-EPMC8511962 | biostudies-literature
| S-EPMC8258323 | biostudies-literature
| S-EPMC7198370 | biostudies-literature
| S-EPMC5600720 | biostudies-literature
| S-EPMC4490627 | biostudies-literature
| S-EPMC6406485 | biostudies-literature